License and Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2025

License And Collaboration Agreements [Abstract]

Summary of Research and Development Costs Related to Collaboration and License Agreements

The following table summarizes each party’s respective share of costs incurred and paid by the other party for zipalertinib development activities for 2025 and 2024 (in thousands):

	2025		2024
Cullinan's share of zipalertinib research and development costs incurred by Taiho	$	28,401	$	24,909
Cullinan’s share of general and administrative costs incurred by Taiho	$	3,247	$	2,051
Taiho’s share of research and development costs incurred by Cullinan	$	7,640	$	9,549